Research Paper Volume 13, Issue 8 pp 12207—12223
Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1
Figure 1. SOX2-mediated lncRNA CCAT1 promotes EGFR expression in HepG2 cells. (A) SOX2 and CCAT1 expression in normal liver (n = 28), para-cancerous (n = 68) and HCC tissues (n = 68) detected by RT-qPCR normalized to β-actin. (B) SOX2 mRNA expression in human HCC cell lines detected by RT-qPCR. (C) CCAT1 expression in human HCC cell lines detected by RT-qPCR. (D) Interaction of SOX2 with CCAT1 in HepG2 cell line detected using EMSA. (E) ChIP-qPCR results of the binding of SOX2 to CCAT1 promoter region in HepG2 cell line. (F) SOX2 expression and CCAT1 and EGFR mRNA expression after alteration of SOX2 and CCAT1 in HepG2 cells detected by RT-qPCR. * p < 0.05 vs. normal liver cell, LO2 or HepG2 treated with sh-NC + oe-NC. # p < 0.05 vs. HepG2 treated with sh-SOX2 + oe-NC. & p < 0.05 vs. HepG2 treated with sh-SOX2 + oe-NC. Data are expressed as mean ± standard deviation. Data comparisons among multiple groups were performed by one-way ANOVA and Tukey’s post hoc test.